CIRIFOUR

CIRIFOUR

In 2020, Cantargia initiated a second clinical trial, the phase Ib study CIRIFOUR, in which nadunolimab (CAN04) is combined with the checkpoint inhibitor Keytruda® (pembrolizumab), an immunotherapy established as standard of care for several cancer forms assessed in the study: non-small cell lung cancer (NSCLC), bladder cancer, head and neck cancer (HNSCC), and malignant melanoma. 

There is a considerable body of research indicating that treatment with CAN04 and immunotherapy may be synergistic. In CIRIFOUR, patients no longer responding to immunotherapy treatment, received CAN04.

CIRIFOUR is conducted at three US clinical centers, with University of Pennsylvania being the lead center. The patient recruitment to the study has been completed and a total of 16 patients have been treated. The primary objective of this study is to assess the safety of CAN04 in combination with pembrolizumab and to establish a recommended dose of CAN04 in this combination. Secondary objectives include assessment of clinical activity and biomarkers. Preliminary results show that the combination has a very favorable safety profile. Interim efficacy data were reported at ASCO 2022 and are summarized here.

A final read-out from the patients in CIRIFOUR is expected in H2 2023.

Read more about CIRIFOUR on ClinicalTrials.gov (NCT04452214).